Emma Walmsley, the chief executive of GSK, described the collaboration as “unprecedented”.
葛兰素史克首席执行官埃玛·沃姆斯利称,这一合作“前所未有”。
She said: “What is not common is you’ve got two of the biggest vaccine manufacturers in the world coming together. Both bring significant manufacturing capacity. We believe we’ll be able to make hundreds of millions of doses by the end of next year.”
她说:“世界上最大的两家疫苗生产商走到一起,这并不常见。二者都会带来巨大的生产能力。我们相信,到明年年底,我们将能够生产出数亿剂 Paul Hudson, the chief executive of Sanofi, said: “As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone. That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus.”
赛诺菲首席执行官保罗·赫德森说:“在世界面临这一前所未有的全球性卫生危机之际,显然没有任何一家企业能够单打独斗。正因为如此,赛诺菲将继续与葛兰素史克等同行企业互相补充专业技能和资源,目标是生产和供应足够数量的疫苗,从而帮助遏制新冠病毒。”
Sanofi, which is headquartered in France, announced in February that it was entering the race to make a vaccine and had secured support from the US health department.
【英法制药巨头联手研发新冠疫苗 明年或大量上市】相关文章:
★ 巴菲特投资太阳能
★ 聪明的熊猫
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15